This Week’s Biopharma News: Novo Nordisk Board Shakeup
October 28, 2025
This week’s news roundup reports on the boardroom reshuffle at Novo Nordisk, Novartis’ neuromuscular expansion, GSK’s Global Fund pledge and more.
4 min read
False
Advertisement
Latest
Get Ready for Day 2 of CPHI 2025: Sustainability Power Hour
October 28, 2025
We select highlights from the show’s agenda
3 min read
Reimagining Antibody Drug Discovery with AI
October 27, 2025
By focusing on functional activity, Abalone Bio is advancing CB2-targeting antibodies with the potential to transform treatment for fibrosis, neuropathy, and beyond.
6 min read
MDIs and the Need for Greener Propellants
By Stephanie Vine, Julian Upton
October 27, 2025
Regulations are pushing companies to more environmentally friendly propellants, but how should capacity be scaled up?
5 min read
Get Ready for CPHI: Off-Patent Semaglutide and Sustainability in a Shifting World
October 27, 2025
It’s showtime in Frankfurt – with around 62,000 attendees expected.
4 min read
Reimagining LSD to Treat Mental Health Disorders
By Stephanie Vine
October 24, 2025
We speak with a biotech CEO about the potential of psychedelic medicine – and the challenges of working with stigmatized substances.
11 min read
Hedgehogs, Seaweed, and the Future of Cell Logistics
October 24, 2025
How biology, sustainability, and a nod to the African pygmy hedgehog are reshaping how we move living cells around the world – and beyond.
6 min read
Made in Africa, For Global Good
By Stephanie Vine
October 23, 2025
Interviewing Quarraisha Abdool Karim – one of the world’s most influential HIV scientists
10 min read
Roving Reporter Asks: What Are the Biggest Hurdles in Cell and Gene Therapy Development?
October 23, 2025
IBTV interviews show that funding and investment panic are dominating industry concerns.
The Cell & Gene Circuit: Keeping Up With Advancing Therapies and Technologies
October 22, 2025
Cell and gene therapy is advancing faster than ever, powered by breakthroughs in AI, automation, and CRISPR technology. But as some companies double down and others step back, the race to deliver real-world impact is intensifying.
4 min read
